Two Canadian companies have made a splash advancing personalized medicine in both the US and Canada. Zymeworks raised $85 million in its IPO to advance the development of disruptive therapeutic platforms and biotherapeutics – the first Canadian venture-backed IPO in the life sciences sector since 2014. Additionally, Repare Therapeutics Inc. announced a US$68 million Series A financing financing to advance its platform and pipeline of novel medicines that target genetically defined weaknesses of cancers. Together, these companies demonstrate the increasing force of personalized medicine on the Canadian bioeconomy.